Peppermint et al. invest in IOP

The investment marked the second closing of the company's series-A round, bringing the total amount raised to €3m. The previous round comprised €1.4m from Hannover Beteiligungsfonds, High-Tech Gründerfonds and a group of private medical technology investors.

The business will use the capital to bring its new diagnostics system to market via a CE trial. IOP plans to expand its clinical studies in Europe, start an IDE pilot study in the US and develop its system for remote glaucoma patient management.

Company
IOP develops systems for monitoring chronic eye diseases such as glaucoma. The company is based in Hannover.

Its first product is an intra-ocular sensor currently being trialled for CE approval. Its system consists of a micro-sensor implanted into the eye and a handheld unit. It enables early diagnosis of glaucoma and monitors its progression and therapy. The company plans to embed its product in a telemedical diagnostic platform in the future, connecting patients with doctors.

IOP was founded in 2010 and employs four staff. The company is looking to hire an additional 2-3 people in the coming weeks.

People
Klaus Stöckemann is a managing director at Peppermint and its Peppermint Charité Biomedical fund. Sven Close is a senior investment manager at Enjoy Venture.

Advisers
Equity – SJ Berwin (Legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Early-stage
• High-Tech Gründerfonds
• Beteiligungskapital Hannover
• Germany
• SJ Berwin